Home » SANKYO SELECTED EVOTEC AS ASSAY DEVELOPMENT AND SCREENING
SANKYO SELECTED EVOTEC AS ASSAY DEVELOPMENT AND SCREENING
Evotec AG has announced that Sankyo has chosen Evotec as a partner to identify small molecule therapeutics for their pharmaceutical discovery projects. Evotec will apply their skills and proprietary technologies in assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with disease targets selected by Sankyo.
HTScreening.net (http://www.htscreening.net/index.aspx?ID=72023)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct